A Phase I Study of Cipatinib in Patients With HER2 Positive or Uncertain Advanced Breast Cancer.
Phase of Trial: Phase I
Latest Information Update: 20 Dec 2012
At a glance
- Drugs Lapatinib (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- 01 Nov 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 04 Jan 2012 Planned end date changed from 1 Dec 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.
- 03 Mar 2011 New trial record